DRAFT – not reviewed. Not for publication until checked by a medical expert and approved by the CannaQ owner.
CannaQ

CannaQ › Blog › Epilepsy

DRAFT – not reviewed

Cannabidiol in Dravet and Lennox–Gastaut syndromes: what the phase 3 trials found

Three placebo-controlled trials tested a pharmaceutical cannabidiol (CBD) oral solution in two rare, severe childhood-onset epilepsies. Here is what they measured, what they found and what they leave open.

EpilepsyEvidence type: Randomised controlled trialsLast checked: Status: draft, awaiting medical expert review

Key points

  • Three randomised, double-blind, placebo-controlled phase 3 trials (516 participants in total) studied cannabidiol added to existing anti-seizure treatment in Dravet syndrome and Lennox–Gastaut syndrome.[1,2,3]
  • In all three trials, the main seizure outcome was reduced more with cannabidiol than with placebo over 14 weeks.[1,2,3]
  • Adverse events were more common with cannabidiol, including sleepiness, diarrhoea, reduced appetite and raised liver enzyme results, and more people stopped treatment because of side effects.[1,2,3]
  • The results apply to the specific product, conditions and study populations tested. They are not evidence about other cannabis or CBD products, or about other types of epilepsy.

The conditions

Dravet syndrome is described by the trial authors as a complex childhood epilepsy disorder associated with drug-resistant seizures and a high mortality rate.[1] Lennox–Gastaut syndrome is described as a rare, severe developmental epileptic encephalopathy whose seizures are frequently resistant to available medications.[2,3] The main outcome in each trial was a change in the frequency of a specific seizure type: convulsive seizures in Dravet syndrome and drop seizures in Lennox–Gastaut syndrome.

The trials

TrialConditionParticipantsDesign
GWPCARE1[1,4]Dravet syndrome120 children and young adultsCannabidiol oral solution or placebo, added to standard treatment; 14-week treatment period
GWPCARE3[2,5]Lennox–Gastaut syndrome225, aged 2–55 yearsTwo cannabidiol dose groups or placebo, added to existing treatment; 14 weeks; 30 centres
GWPCARE4[3,6]Lennox–Gastaut syndrome171, aged 2–55 yearsCannabidiol or placebo, added to existing treatment; 14 weeks; 24 sites in the USA, the Netherlands and Poland

All three were funded by GW Pharmaceuticals.[1,2,3] The ClinicalTrials.gov records now list Jazz Pharmaceuticals as lead sponsor, show all three as completed and report that results have been posted.[4,5,6]

What they found

Dravet syndrome (GWPCARE1)

The median frequency of convulsive seizures per month fell from 12.4 to 5.9 with cannabidiol, compared with 14.9 to 14.1 with placebo. The adjusted median difference between groups was −22.8 percentage points (95% CI −41.1 to −5.4).[1] Some other results did not reach statistical significance: at least a 50% reduction in convulsive seizures occurred in 43% with cannabidiol and 27% with placebo (P=0.08), and 5% versus 0% became seizure-free (P=0.08). There was no significant reduction in non-convulsive seizures.[1]

Lennox–Gastaut syndrome (GWPCARE3 and GWPCARE4)

In GWPCARE3, the median reduction in drop-seizure frequency was 41.9% and 37.2% in the two cannabidiol groups, compared with 17.2% with placebo.[2] In GWPCARE4, the median reduction was 43.9% with cannabidiol and 21.8% with placebo, an estimated median difference of −17.21 (95% CI −30.32 to −4.09).[3]

Side effects reported

What these trials do not show

  • They lasted 14 weeks. Long-term effects were to be studied separately in open-label extensions.[3]
  • Cannabidiol was given in addition to existing anti-seizure medicines, not instead of them.[1,2,3]
  • They studied a specific pharmaceutical oral solution in two specific syndromes. They do not tell us how other CBD or cannabis products behave, which can differ in content and quality.
  • All three were industry-funded. That does not make the results wrong, but it is part of reading them carefully.

This summary is not a guide to treatment. Questions about treatment belong with the treating specialist.

Medical disclaimer. Educational content only, not medical advice. Legal status varies by country. Consult a qualified healthcare professional. This article summarises published research. It does not recommend any treatment, product or dose, and it is not a substitute for advice from a healthcare professional who knows your situation.

References

All identifiers below were retrieved and checked on 2026-11-17 through PubMed E-utilities, the Europe PMC REST API and the ClinicalTrials.gov API v2.

  1. Devinsky O, Cross JH, Laux L, et al.; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020. PMID: 28538134. DOI: 10.1056/NEJMoa1611618.
  2. Devinsky O, Patel AD, Cross JH, et al.; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897. PMID: 29768152. DOI: 10.1056/NEJMoa1714631.
  3. Thiele EA, Marsh ED, French JA, et al.; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox–Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–1096. PMID: 29395273. DOI: 10.1016/S0140-6736(18)30136-3.
  4. ClinicalTrials.gov. Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1). Phase 3; completed; 120 enrolled. NCT02091375.
  5. ClinicalTrials.gov. Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3). Phase 3; completed; 225 enrolled. NCT02224560.
  6. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE4). Phase 3; completed; 171 enrolled. NCT02224690.
Review notes (internal, remove before publication): All figures are taken from the PubMed abstracts only; full texts were not read. Trial doses were deliberately left out to avoid any dosing interpretation. Not stated, because not checked: current regulatory approval status of any CBD medicine in any country, and the open-label extension results. The point that the findings do not extend to other CBD products is an editorial caution, not a finding of these trials, and should be confirmed by the reviewer. Europe PMC listed no retractions or corrections for references 1–3 on 2026-11-17.

← All articles · How CannaQ grades evidence